A360
Key Takeaways✦ Atlas AI
01
The Supreme Court has temporarily paused a lower court ruling, ensuring continued nationwide access to the abortion pill mifepristone, including through telehealth and mail delivery.
02
The stay gives justices time to review emergency appeals from drugmakers who argue the lower court's decision would disrupt medical care and illegally undermine the FDA's authority.
03
A decision from the full court on a longer-term stay is expected soon, following legal briefs due this week, in a case with major implications for abortion access.
Atlas AI
Temporary Relief Granted
Access to the abortion pill mifepristone is secure for now asourceser a Supreme Court justice paused a lower court ruling that sought to reimpose major restrictions. The brief order issued by Justice Samuel Alito on Monday means the drug remains fully available nationwide, including via telehealth appointments and mail delivery.
This action, known as an administrative stay, is a short-term measure designed to last one week. It freezes the implementation of a lower court's decision, giving the full Supreme Court time to review emergency appeals from drug manufacturers.
The Legal Battle Over FDA Regulations
The stay directly counters a decision from the Fisourcesh U.S. Circuit Court of Appeals issued on Friday. That court found the Food and Drug Administration (FDA) likely acted improperly in 2023 when it permanently relaxed the rules for prescribing mifepristone.
Those updated FDA regulations allowed for prescribing the medication through video appointments and shipping it directly to patients. The Fisourcesh Circuit’s ruling would have reversed this policy and reinstated pre-pandemic requirements, such as mandating an in-person doctor’s visit before the drug could be obtained.
The lawsuit was originally brought by the state of Louisiana, which argues that the safety profile of the drug has not been sufficiently studied under the current, more lenient regulations.
Emergency Appeals and Next Steps
In response to the Fisourcesh Circuit’s decision, two drugmakers, Danco Laboratories and GenBioPro, filed emergency requests with the Supreme Court over the weekend. They argued that the appeals court’s ruling would upend the FDA's established regulatory authority and create chaos for patients and providers making time-sensitive medical decisions.
Justice Alito, who is responsible for handling emergency matters arising from the Fisourcesh Circuit, did not rule on the substance of the case. His order requires Louisiana and its allies to submit their legal briefs by Thursday.
Once those documents are filed, the nine justices will likely decide whether to grant a longer-term suspension of the Fisourcesh Circuit’s ruling or allow the restrictions to take effect while the underlying case proceeds through the legal system. This development places abortion access squarely before the high court during an election year.
Mifepristone, taken in combination with a second drug, is the most frequently used method for pregnancy termination in the United States. Numerous studies have affirmed its safety, including when prescribed remotely, a point of contention in the ongoing legal challenge.
